Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan method could improve fungal infection care in cancer patients

NCT ID NCT02955966

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a special type of scan (PET/CT) can help doctors see if treatment for a serious fungal lung infection is working earlier than usual. It involved 51 adults with blood cancer and invasive pulmonary aspergillosis. The goal was to see if the scan results matched other lab tests and could guide treatment decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

51 people

The number who actually took part.

Started

Jun 2017

Finished

May 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients ≥18 years-old * Patient with hematological malignancy * Proven or probable invasive pulmonary aspergillosis according to EORTC/MSG modified criteria * Inclusion ≤ 4 days (≤ 5 days in case of week end) after IPA diagnosis * Possibility to perform 18F-FDG-PET/CT scanner within the 7 subsequent days following diagnosis * Informed consent form signed * Affiliation to French social insurance Exclusion Criteria: * Pregnancy or breastfeeding women * Life expectancy \< 3 months * Fungal or mycobacterial lung co infection at time of IPA diagnosis * Haematological malignancy with lung location * Proven or probable mold infection in 6 previous months * Disseminated aspergillosis (lung and sinus aspergillosis can be included)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aspergillosis and haematological malignancy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aspergillosis hematopoietic and lymphoid system neoplasm invasive aspergillosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aspergillosis and haematological malignancy

Contacts and locations

Locations

  • Department of Infectious Diseases and Tropical Medicine, Necker enfants malades hospital

    Paris, Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.